209 related articles for article (PubMed ID: 34302286)
1. Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation.
Li RJ; Caughey GE; Shakib S
J Thromb Thrombolysis; 2022 Feb; 53(2):425-435. PubMed ID: 34302286
[TBL] [Abstract][Full Text] [Related]
2. Direct Oral Anticoagulants and Non-valvular Atrial Fibrillation: Compliance with Dose Level Guidelines in Patients Aged 80 Years and Over.
Cavillon Decaestecker M; Ferret L; Decaestecker K; Gautier S; Verdun S; Tsogli ES
Drugs Aging; 2021 Oct; 38(10):939-950. PubMed ID: 34486094
[TBL] [Abstract][Full Text] [Related]
3. Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database.
Khachatryan A; Doobaree IU; Spentzouris G; Gusto G; Zawaneh Y; Mughal F; Anastassopoulou A; Manu M; Fay M
Adv Ther; 2023 Feb; 40(2):504-520. PubMed ID: 36399317
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and factors associated with inappropriate dosing of apixaban and rivaroxaban in hospitalized older adults with atrial fibrillation: a cross-sectional study.
Decaix T; Kemache K; Gay P; Laprévote O; Ketz F; Pautas É
Drugs Aging; 2024 Jan; 41(1):55-64. PubMed ID: 37957440
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF.
Guenoun M; Cohen S; Villaceque M; Sharareh A; Schwartz J; Hoffman O; Dib JC; Ouazana L; Assouline S; Parrens E; Garban T; Pradeau V; Guedj-Meynier D; Lequeux B; Cohen C; Durand P; Dievart F; Dhanjal TS; Sabouret P; Lellouche N
Europace; 2023 Oct; 25(10):. PubMed ID: 37801642
[TBL] [Abstract][Full Text] [Related]
6. Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study.
Lau WCY; Cheung CL; Man KKC; Chan EW; Sing CW; Lip GYH; Siu CW; Lam JKY; Lee ACH; Wong ICK
Ann Intern Med; 2020 Jul; 173(1):1-9. PubMed ID: 32423351
[TBL] [Abstract][Full Text] [Related]
7. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK.
García Rodríguez LA; Martín-Pérez M; Vora P; Roberts L; Balabanova Y; Brobert G; Fatoba S; Suzart-Woischnik K; Schaefer B; Ruigomez A
BMJ Open; 2019 Sep; 9(9):e031341. PubMed ID: 31542760
[TBL] [Abstract][Full Text] [Related]
8. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
[TBL] [Abstract][Full Text] [Related]
9. Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients With Atrial Fibrillation in the United States.
Sandhu A; Kaltenbach LA; Chiswell K; Shimoga V; Ashur C; Pribish A; Fonarow GC; Piccini JP; Ho PM; Varosy PD; Hess PL
Circ Cardiovasc Qual Outcomes; 2023 Dec; 16(12):e010062. PubMed ID: 37929603
[TBL] [Abstract][Full Text] [Related]
10. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
[TBL] [Abstract][Full Text] [Related]
11. The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation.
Fanning L; Ilomäki J; Bell JS; Dārziņš P
Eur J Clin Pharmacol; 2017 Nov; 73(11):1427-1436. PubMed ID: 28752255
[TBL] [Abstract][Full Text] [Related]
12. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
Baker CL; Dhamane AD; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Menges B; Lin J; Nadkarni A
Adv Ther; 2019 Jan; 36(1):162-174. PubMed ID: 30499067
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
Feldberg J; Patel P; Farrell A; Sivarajahkumar S; Cameron K; Ma J; Battistella M
Nephrol Dial Transplant; 2019 Feb; 34(2):265-277. PubMed ID: 29509922
[TBL] [Abstract][Full Text] [Related]
15. Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation.
Baker D; Wilsmore B; Narasimhan S
Intern Med J; 2016 Jul; 46(7):792-7. PubMed ID: 27040617
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
Lip GYH; Keshishian A; Li X; Hamilton M; Masseria C; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Baser O; Deitelzweig S
Stroke; 2018 Dec; 49(12):2933-2944. PubMed ID: 30571400
[TBL] [Abstract][Full Text] [Related]
17. Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study.
Miyazaki M; Matsuo K; Uchiyama M; Nakamura Y; Sakamoto Y; Misaki M; Tokura K; Jimi S; Okamura K; Adachi S; Yamamoto T; Shirai K; Urata H; Imakyure O
J Pharm Health Care Sci; 2020; 6():2. PubMed ID: 32071730
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Sood NA; Bunz TJ; Coleman CI
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
[TBL] [Abstract][Full Text] [Related]
19. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
